by NanoLogix | May 3, 2020 | updates
Last week NanoLogix completed development testing of a unique Coronavirus (COVID-19) detection technology with sub 1-hour results and exceptional sensitivity and accuracy. The technology has the potential to be configured as a Point of Care (POC) and also for...
by NanoLogix | Aug 2, 2018 | updates
Jonathan Faro, PhD, MD, joins as Director of Medical Development NanoLogix is pleased to announce the addition of Jonathan Faro, PhD, MD to the Company’s Board of Directors. Dr. Faro is the co-inventor of the N-Assay modified ELISA bacteria-detection and...
by NanoLogix | Apr 28, 2017 | updates
NanoLogix is pleased to announce that the N-Assay Bacteria Diagnostic, recently configured for detection and identification of a rare Deinococcus bacteria species, will be presented in poster format at the American Association for Clinical Chemistry (AACC) 69th Annual...
by NanoLogix | Aug 14, 2014 | updates
HUBBARD, Ohio–(BUSINESS WIRE)–NanoLogix Inc. (NNLX), an innovative biotechnology company in Northeastern Ohio announces that it is configuring its N-Assay Rapid diagnostic kits for both Ebola Virus and Enterovirus detection and identification. NanoLogix...
by NanoLogix | Aug 1, 2011 | updates
NanoLogix Group B Streptococcus Quick Test technology is currently undergoing a 300-patient clinical study at the University of Texas Health Science Center (UTHSC). Preliminary results published in the American Journal of Perinatology (August 2011) “Rapid...
